A
April Barbour
Researcher at George Washington University
Publications - 9
Citations - 566
April Barbour is an academic researcher from George Washington University. The author has contributed to research in topics: Pharmacogenomics & VKORC1. The author has an hindex of 5, co-authored 9 publications receiving 444 citations.
Papers
More filters
Journal ArticleDOI
American Cancer Society Colorectal Cancer Survivorship Care Guidelines
Khaled El-Shami,Kevin C. Oeffinger,Nicole L. Erb,Anne Willis,Jennifer K. Bretsch,Mandi Pratt-Chapman,Rachel S. Cannady,Sandra L. Wong,Johnie Rose,April Barbour,Kevin Stein,Katherine Sharpe,Durado Brooks,Rebecca Cowens-Alvarado +13 more
TL;DR: In this paper, the authors present guidelines to assist primary care clinicians in delivering risk-based health care for colorectal cancer survivors who have completed active therapy, including communication and coordination of care between the treating oncologist and the primary care clinician to effectively manage the long-term care of CRC survivors.
Journal ArticleDOI
Pediatric to Adult Transition: A Quality Improvement Model for Primary Care
Margaret A. McManus,Patience H. White,April Barbour,Billie Downing,Kirsten B. Hawkins,Nathalie Quion,Lisa Tuchman,Carl Cooley,Jeanne W. McAllister +8 more
TL;DR: Quality improvement using the Six Core Elements of Health Care Transition resulted in the development of a systematic clinical transition process in pediatric and adult academic primary care practices.
Journal ArticleDOI
Ethnicity-Specific Pharmacogenetics: The Case of Warfarin In African Americans
Wenndy Hernandez,Eric R. Gamazon,Keston Aquino-Michaels,Shitalben R. Patel,Travis J. O’Brien,Arthur F. Harralson,Arthur F. Harralson,Rick A. Kittles,April Barbour,Matthew Tuck,Samantha D. McIntosh,Samantha D. McIntosh,Jacqueline N. Douglas,Dan L. Nicolae,Larisa H. Cavallari,Minoli A. Perera +15 more
TL;DR: The first warfarin dosing algorithm that includes recently discovered polymorphisms in VKORC1 and CYP2C9 associated with warfar in African Americans AAs is developed and compared to the International Warfarin Pharmacogenetics Consortium (IWPC) dosing algorithms.
Journal ArticleDOI
Novel genetic predictors of venous thromboembolism risk in African Americans
Wenndy Hernandez,Eric R. Gamazon,Eric R. Gamazon,Erin Smithberger,Travis J. O’Brien,Arthur F. Harralson,Arthur F. Harralson,Matthew Tuck,April Barbour,Rick A. Kittles,Larisa H. Cavallari,Minoli A. Perera +11 more
TL;DR: The first genome-wide association study in AAs, comprising 578 subjects, followed by replication of highly significant findings in an independent cohort of 159 AA subjects, provides new molecular insight into a mechanism regulating VTE susceptibility and identifies common genetic variants that increase the risk of VTE in Aas.
Journal ArticleDOI
First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele.
Travis J. O’Brien,Robert S. Kidd,Craig A.H. Richard,Ngoc Han Ha,Preston Witcher,Linda V. Tran,April Barbour,Matthew Tuck,Matthew Tuck,Matthew Tuck,Samantha D. McIntosh,Samantha D. McIntosh,Jacqueline N. Douglas,Arthur F. Harralson,Arthur F. Harralson +14 more
TL;DR: This is the first report of patients with the rare CYP2C9*12 genotype and lower warfarin dose requirements and individual comparisons with patients possessing the same VKORC1 and APOE genotypes demonstrated lower dose requirements.